Sorrento Therapeutics Hits Ch. 11 With Over $100M In Debt
California pharmaceutical research firm Sorrento Therapeutics Inc., a developer of cancer, COVID-19 and chronic pain treatments, filed for Chapter 11 protection in a Texas bankruptcy court Monday with about $135 million...To view the full article, register now.
Already a subscriber? Click here to view full article